Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase NA 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Genitourinary 1

Conditions

Hyperparathyroidism 2Parathyroid Neoplasms 1Neoplasm Metastasis 1Hyperparathyroidism, Secondary 1Hyperparathyroidism, Primary 1Chronic Kidney Disease-Mineral and Bone Disorder 1

Interventions

Cisplatin 5lenvatinib 4Fentanyl 4Morphine 3Fluorouracil 3Docetaxel 3trametinib 2selpercatinib 2pralsetinib 2pembrolizumab 2nimotuzumab 2larotrectinib 2dabrafenib 2cabozantinib 2anlotinib 2Thyrotropin Alfa 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Norepinephrine 2Metformin 2Indocyanine Green 2Gabapentin 2Cinacalcet 2Cetuximab 2Carboplatin 2Benzydamine 2Acetaminophen 2xiaojin wan 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Cinacalcet × Head & Neck × Clear all
NCT03123406 2024-04-29

ACTIVE

Kyowa Kirin Co., Ltd.

Phase 4 Completed
750 enrolled
GenitourinaryHead & Neck

Hyperparathyroidism, Hyperparathyroidism, Secondary, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder

NCT00037518 2013-05-08

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Amgen

Phase 4 Completed
46 enrolled
Head & Neck

Hyperparathyroidism, Parathyroid Neoplasms, Hyperparathyroidism, Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡